Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.

Abstract: Disclosed are methods of treating colorectal cancer that involve administering a composition comprising an effective amount of miR-451a to cells in the colorectal cancer and further treating the colorectal cancer cells with ionizing radiation. Also disclosed are methods of predicting whether a colorectal cancer in a subject will respond to ionizing radiation. These methods involve measuring the RNA expression of miR-451a, miR-1322, miR-133-3p, miR-1, miR-205-5p, miR-4521, CAB39, EMSY, or MEX3C in the sample and measuring the RNA expression of the same marker in a control.

Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.

Abstract: Disclosed are methods and systems correcting bulk-motion artifacts in phase-based functional OCT images. The disclosed methods and systems are based on the use of the standard deviation of the phase shift signal present in phase-based OCT imaging. When applied with functional OCT techniques such as OCT angiography, Doppler OCT, and OCT elastography, the disclosed methods provide improved image quality and decreased computational cost compared to other methods of bulk motion compensation.

Abstract: Provided herein are novel amide prodrug forms of pharmaceutically active agents useful for central nervous system disorders.

Abstract: Apparatuses and methods for dried blood spot (DBS) sample collection are disclosed. A dried blood spot sampling device is configured to deliver blood through a passage to an absorbent disk in the device and control an amount of blood saturating the absorbent disk. The sampling device may include a manually actuatable component adjustable between a first position, in which an outlet of the passage is not in physical contact with the absorbent disk, and a second position, in which the outlet of the passage is in physical contact with the absorbent disk.

Abstract: MicroRNA inhibitors as anti-cancer therapeutics are described. The microRNA inhibitors can inhibit microRNA-15a and can mimic the effects of higher dose radiation at lower doses. Other benefits are also described.

Abstract: Methods for automatically identifying retinal boundaries from a reflectance image are disclosed. An example of the method includes identifying a reflectance image of the retina of a subject; generating a gradient map of the reflectance image, the gradient map representing dark-to-light or light-to-dark reflectance differentials between adjacent pixel pairs in the reflectance image; generating a guidance point array corresponding to a retinal layer boundary depicted in the reflectance image using the gradient map; generating multiple candidate paths estimating the retinal layer boundary in the reflectance image by performing a guided bidirectional graph search on the reflectance image using the guidance point array; and identifying the retinal layer boundary by merging two or more of the multiple candidate paths.

Abstract: Co-administration (for example, immunogenic cocktail compositions and/or prime boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides is provided. Coadministration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (for example, a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.

Abstract: Methods of applying OCT angiography are disclosed. In particular, methods of detecting, visualizing and measuring the extent of retinal neovascularization are disclosed. Further disclosed are methods measuring retinal nonperfusion area and choriocapillaris defect area.

Abstract: The present disclosure provides ophthalmic compositions containing resveratrol. Also provided are methods of using ophthalmic resveratrol compositions to treat acute ocular pain, chronic ocular pain, dry eye disease, and/or photophobia.

Abstract: Disclosed herein are methods and systems for capillary oximetry (e.g., retinal capillary oximetry) using optical coherence tomography (OCT). The method may include obtaining an OCT angiography dataset, performing capillary segmentation based on the OCT angiography dataset to obtain capillary segments, resampling, registering, and/or averaging B-scans of the OCT angiography dataset that correspond to a first capillary segment of the capillary segments to obtain an averaged B-scan for the first capillary segment, determining an anterior and posterior border of the first capillary segment, and determining an oxygen saturation of the first capillary segment based on the averaged B-scan, the anterior border, and the posterior border. Other embodiments may be described and claimed.

Abstract: Radiofluorinated FNDP for PET imaging of soluble epoxide hydrolase (sEH) and method of using the same are disclosed.

Abstract: Disclosed herein are therapeutic constructs including a delivery particle, at least one mitotic kinase inhibitor, and at least one immune checkpoint inhibitor. Also disclosed are therapeutic constructs including a mitotic kinase inhibitor, an immune checkpoint inhibitor, and a chemical linker. These therapeutic constructs cause cancer death by both therapeutic and immune effects and promote targeted delivery of more therapeutics to the surviving cancer cells in a positive feed-back loop. They enhance therapeutic index of free drugs and can be used intratumorally or systemically. This strategy can treat broad cancer types and is particular useful for cancer without obvious receptors for cancer-targeted delivery of otherwise toxic therapeutics.

Abstract: Provided herein are compounds of Formula I, or a pharmaceutically acceptable salt thereof: which are useful as PARP inhibitors, as well as pharmaceutical compositions comprising them and methods for their use in treating disorders.

Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.

Abstract: Compounds are provided that function as thyromimetics, which compounds have utility for treating diseases such as neurodegenerative disorders. Pharmaceutical compositions containing such compounds are also provided, as are methods of their use and preparation. Such compounds have the structure of Formula (I) as shown herein, or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope or salt thereof.

Abstract: Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include administration of a therapeutically effective amount of sobetirome, or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.

Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.